guest ::
| Home > Publications Database > A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis. > print |
| Home > Publications Database > A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis. > print |
| 001 | 277527 | ||
| 005 | 20250323000957.0 | ||
| 024 | 7 | _ | |a 10.1016/j.immuni.2025.01.003 |2 doi |
| 024 | 7 | _ | |a pmid:39879983 |2 pmid |
| 024 | 7 | _ | |a 1074-7613 |2 ISSN |
| 024 | 7 | _ | |a 1097-4180 |2 ISSN |
| 024 | 7 | _ | |a altmetric:173590433 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-00423 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Asare, Yaw |b 0 |
| 245 | _ | _ | |a A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis. |
| 260 | _ | _ | |a [Cambridge, Mass.] |c 2025 |b Cell Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1742379668_6428 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Common genetic variants in a conserved cis-regulatory element (CRE) at histone deacetylase (HDAC)9 are a major risk factor for cardiovascular disease, including stroke and coronary artery disease. Given the consistency of this association and its proinflammatory properties, we examined the mechanisms whereby HDAC9 regulates vascular inflammation. HDAC9 bound and mediated deacetylation of NLRP3 in the NACHT and LRR domains leading to inflammasome activation and lytic cell death. Targeted deletion of the critical CRE in mice increased Hdac9 expression in myeloid cells to exacerbate inflammasome-dependent chronic inflammation. In human carotid endarterectomy samples, increased HDAC9 expression was associated with atheroprogression and clinical plaque instability. Incorporation of TMP195, a class IIa HDAC inhibitor, into lipoprotein-based nanoparticles to target HDAC9 at the site of myeloid-driven vascular inflammation stabilized atherosclerotic plaques, implying a lower risk of plaque rupture and cardiovascular events. Our findings link HDAC9 to atherogenic inflammation and provide a paradigm for anti-inflammatory therapeutics for atherosclerosis. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a GWAS |2 Other |
| 650 | _ | 7 | |a HDAC9 |2 Other |
| 650 | _ | 7 | |a NLRP3 |2 Other |
| 650 | _ | 7 | |a atherosclerosis |2 Other |
| 650 | _ | 7 | |a cis-regulatory element |2 Other |
| 650 | _ | 7 | |a inflammasome |2 Other |
| 650 | _ | 7 | |a inflammation |2 Other |
| 650 | _ | 7 | |a nanobiologics |2 Other |
| 650 | _ | 7 | |a stroke |2 Other |
| 650 | _ | 7 | |a therapeutics |2 Other |
| 650 | _ | 7 | |a Histone Deacetylases |0 EC 3.5.1.98 |2 NLM Chemicals |
| 650 | _ | 7 | |a Inflammasomes |2 NLM Chemicals |
| 650 | _ | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a HDAC9 protein, human |0 EC 3.5.1.98 |2 NLM Chemicals |
| 650 | _ | 7 | |a Hdac9 protein, mouse |0 EC 3.5.1.98 |2 NLM Chemicals |
| 650 | _ | 7 | |a Repressor Proteins |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Atherosclerosis: genetics |2 MeSH |
| 650 | _ | 2 | |a Atherosclerosis: metabolism |2 MeSH |
| 650 | _ | 2 | |a Atherosclerosis: immunology |2 MeSH |
| 650 | _ | 2 | |a Histone Deacetylases: metabolism |2 MeSH |
| 650 | _ | 2 | |a Histone Deacetylases: genetics |2 MeSH |
| 650 | _ | 2 | |a Inflammasomes: metabolism |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Inflammation: genetics |2 MeSH |
| 650 | _ | 2 | |a NLR Family, Pyrin Domain-Containing 3 Protein: metabolism |2 MeSH |
| 650 | _ | 2 | |a NLR Family, Pyrin Domain-Containing 3 Protein: genetics |2 MeSH |
| 650 | _ | 2 | |a Repressor Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Repressor Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Mice, Knockout |2 MeSH |
| 650 | _ | 2 | |a Regulatory Sequences, Nucleic Acid: genetics |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a Plaque, Atherosclerotic: metabolism |2 MeSH |
| 650 | _ | 2 | |a Plaque, Atherosclerotic: genetics |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Regulation |2 MeSH |
| 700 | 1 | _ | |a Yan, Guangyao |b 1 |
| 700 | 1 | _ | |a Schlegl, Christina |b 2 |
| 700 | 1 | _ | |a Prestel, Matthias |0 P:(DE-2719)9001400 |b 3 |u dzne |
| 700 | 1 | _ | |a van der Vorst, Emiel P C |b 4 |
| 700 | 1 | _ | |a Teunissen, Abraham J P |b 5 |
| 700 | 1 | _ | |a Aronova, Arailym |b 6 |
| 700 | 1 | _ | |a Tosato, Federica |b 7 |
| 700 | 1 | _ | |a Naser, Nawraa |b 8 |
| 700 | 1 | _ | |a Caputo, Julio |b 9 |
| 700 | 1 | _ | |a Prevot, Geoffrey |b 10 |
| 700 | 1 | _ | |a Azzun, Anthony |b 11 |
| 700 | 1 | _ | |a Wefers, Benedikt |0 P:(DE-2719)2810988 |b 12 |u dzne |
| 700 | 1 | _ | |a Wurst, Wolfgang |0 P:(DE-2719)2000028 |b 13 |u dzne |
| 700 | 1 | _ | |a Schneider, Melanie |b 14 |
| 700 | 1 | _ | |a Forne, Ignasi |b 15 |
| 700 | 1 | _ | |a Bidzhekov, Kiril |b 16 |
| 700 | 1 | _ | |a Naumann, Ronald |b 17 |
| 700 | 1 | _ | |a van der Laan, Sander W |b 18 |
| 700 | 1 | _ | |a Brandhofer, Markus |b 19 |
| 700 | 1 | _ | |a Cao, Jiayu |b 20 |
| 700 | 1 | _ | |a Roth, Stefan |b 21 |
| 700 | 1 | _ | |a Malik, Rainer |b 22 |
| 700 | 1 | _ | |a Tiedt, Steffen |b 23 |
| 700 | 1 | _ | |a Mulder, Willem J M |b 24 |
| 700 | 1 | _ | |a Imhof, Axel |b 25 |
| 700 | 1 | _ | |a Liesz, Arthur |b 26 |
| 700 | 1 | _ | |a Weber, Christian |b 27 |
| 700 | 1 | _ | |a Bernhagen, Jürgen |b 28 |
| 700 | 1 | _ | |a Dichgans, Martin |0 P:(DE-2719)2000030 |b 29 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1016/j.immuni.2025.01.003 |g Vol. 58, no. 3, p. 555 - 567.e9 |0 PERI:(DE-600)2001966-X |n 3 |p 555 - 567.e9 |t Immunity |v 58 |y 2025 |x 1074-7613 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/277527/files/DZNE-2025-00423%20SUP.zip |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/277527/files/DZNE-2025-00423.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/277527/files/DZNE-2025-00423.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:277527 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)9001400 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2810988 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2000028 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 29 |6 P:(DE-2719)2000030 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-01-01 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b IMMUNITY : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b IMMUNITY : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-01 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2025-01-01 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 920 | 1 | _ | |0 I:(DE-2719)5000022 |k AG Dichgans |l Vascular Cognitive Impairment & Post-Stroke Dementia |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1140001 |k AG Wurst |l Genome Engineering |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000022 |
| 980 | _ | _ | |a I:(DE-2719)1140001 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|